Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

40.85 -0.10 (-0.24%)
Streaming Delayed Price Updated: 3:46 PM EDT, Jun 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Monday Session
Via Investor Brand Network
SoFi Technologies Posts Q4 Earnings, Joins Cardlytics, McGrath RentCorp And Other Big Stocks Moving Higher On Monday
U.S. stocks traded mixed, with the Dow Jones trading slightly lower on Monday. Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) rose sharply during Monday’s session after the company reported... 
Via Benzinga
Topics Stocks
Exposures US Equities
Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade
On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. 
Via Investor's Business Daily
Recap: Tarsus Pharmaceuticals Q3 Earnings
Via Benzinga
Earnings Preview: Tarsus Pharmaceuticals
Via Benzinga
Expert Ratings for Tarsus Pharmaceuticals
Via Benzinga
Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites
TP-03 demonstrated statistically significant and clinically meaningful improvements across two objective measures of MGD, regardless of BID or TID dosing, and was well tolerated 
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Wynn Resorts Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Wynn Resorts, Limited (NASDAQ: WYNN) fell sharply on Friday after the company reported third-quarter financial results. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Tarsus Pharmaceuticals
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Big Stocks Moving Higher On Friday: Synaptics Reports Q1 Beat; Joins Lyft, Hologic, Blink Charging
U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Friday. Shares of Synaptics Incorporated (NASDAQ: SYNA) rose sharply on Friday after the company reported better-than-expected... 
Via Benzinga
Topics Stocks
Exposures US Equities
Tarsus Pharmaceuticals Inc. (NASDAQ: TARS) Making Surprising Moves in Friday Session
Via Investor Brand Network
Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
HC Wainwright & Co. Maintains Buy Rating for Tarsus Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Earnings Scheduled For November 9, 2023
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million. 
Via Benzinga
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY™, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus to Present at Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Now Available – XDEMVY™ (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for  
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Why Alaska Air Group Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Aurora Acquisition Corp. (NASDAQ: AURC) shares jumped 192% to $30.54. 
Via Benzinga
FDA Approves XDEMVY™ (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
The company's lead therapy is getting close to the finish line of FDA approval. 
Via The Motley Fool
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.